multiple myeloma

News

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a fu

News

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Johnson & Johnson and Legend Biotech will arrive at next week's ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti.

Events

Partner Content

BCMA Targeted Therapies Summit

Revolutionize your BCMA pipeline

News

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA's human medicines commi

News

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development

News

Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod

The US Food and Drug Administration (FDA) has approved a new cell-based therapy for blood cancer, developed by Janssen and China's Legend Biotech to treat multiple myeloma.

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

J&J, Legend get EU nod for myeloma CAR-T Carvykti

BCMA Targeted Therapies Summit

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Janssen, Legend CAR-T therapy CARVYKTI gets FDA nod

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

multiple myeloma

Editor's Picks